Skip to main content
Clinical Trials/ISRCTN31262122
ISRCTN31262122
Completed
未知

PRotective vEntilation with veno-venouS lung assisT in respiratory failure

Belfast Health & Social Care Trust0 sites412 target enrollmentApril 14, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Belfast Health & Social Care Trust
Enrollment
412
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34463700/ (added 20/05/2022) 2023 Other publications in https://doi.org/10.3310/fcdq8036 cost-utility analysis (added 17/10/2023)

Registry
who.int
Start Date
April 14, 2016
End Date
April 30, 2022
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Invasive mechanical ventilation using PEEP \= 5cmH2O\*
  • 2\. Acute and potentially reversible cause of acute respiratory failure as determined by the treating physician
  • 3\. Within 48 hours of the onset of hypoxaemia as defined by PaO2/FiO2 \= 20kPa\*\*
  • \*Recommended on low tidal volume ventilation \= 6 ml/kg PBW
  • \*\*Requires two ABG with a PaO2/FiO2 \= 20kPa separated by at least 6 hours. 48 hour duration begins at the time of 2nd ABG demonstrating PaO2/FiO2 ratio \= 20kPa. Added 05/03/2019: Site will then have a further 8 – 24 hours to randomise and administer the intervention. Added 23/05/2017: The onset of hypoxaemia is from time of intubation and invasive ventilation.
  • (ABGs with PaO2/FiO2 \= 20kPa are permitted between the two trial inclusion ABGs).

Exclusion Criteria

  • Current exclusion criteria as of 23/05/2017:
  • 1\. Age \<16 years old
  • 2\. Intubated and mechanically ventilated via an endotracheal or tracheostomy tube \= 7 days (168 hours) up to the time of randomisation
  • 3\. Ability to maintain Vt to \= 3ml/kg PBW while maintaining pH \= 7\.2 as determined by the treating physician
  • 4\. Receiving, or decision to commence, ECMO in the next 24 hours.
  • 5\. Mechanical ventilation using HFOV or APRV
  • 6\. Untreated pulmonary embolism, pleural effusion or pneumothorax as the primary cause of acute respiratory failure.
  • 7\. Acute respiratory failure fully explained by left ventricular failure or fluid overload (May be determined by clinical assessment or echocardiography/cardiac output monitoring).
  • 8\. Left ventricular failure requiring mechanical support
  • 9\. Contra\-indication to limited systemic anticoagulation with heparin

Outcomes

Primary Outcomes

Not specified

Similar Trials